Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 6.72
+0.08 (1.20%)
Jul 24, 2026, 5:29 PM CET
Egetis Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 63.1 | 62.4 | 46.1 | 57.6 | 22.6 | 38.2 | |
Revenue Growth (YoY) | 34.83% | 35.36% | -19.96% | 154.87% | -40.84% | -6.05% |
Cost of Revenue | 54.2 | 50 | 11.6 | 11 | 6.3 | 7.9 |
Gross Profit | 8.9 | 12.4 | 34.5 | 46.6 | 16.3 | 30.3 |
Selling, General & Admin | 218.4 | 201 | 215.3 | 172.8 | 74.3 | 44.6 |
Depreciation & Amortization Expenses | - | - | - | - | 2.7 | 2.5 |
Research & Development | 156.8 | 158.3 | 146.2 | 194 | 136.3 | 88.7 |
Other Operating Expenses | 2.2 | -6.9 | 2.4 | 4.5 | 1.1 | 0.3 |
Total Operating Expenses | 377.4 | 352.4 | 363.9 | 371.3 | 214.4 | 136.1 |
Operating Income | -368.2 | -339.9 | -329.4 | -324.8 | -198.1 | -105.7 |
Interest Income | 15 | 13.3 | 16.5 | 4.9 | 5 | 1.3 |
Interest Expense | -18 | -22.7 | -25.9 | -4.2 | -0.7 | -0.2 |
Other Non-Operating Income (Expense) | -2.3 | 7.4 | -4.5 | -2.7 | - | - |
Total Non-Operating Income (Expense) | -5.4 | -2.1 | -13.8 | -2 | 4.3 | 1.1 |
Pretax Income | -373.8 | -342.1 | -343.2 | -326.8 | -193.8 | -104.5 |
Provision for Income Taxes | -0.4 | -0.4 | -0.3 | -0.1 | - | - |
Net Income | -254.5 | -341.7 | -342.9 | -326.9 | -193.8 | -104.5 |
Net Income to Common | -279.7 | -342.5 | -343.6 | -326.9 | -193.8 | -104.5 |
Shares Outstanding (Basic) | 377 | 368 | 307 | 257 | 194 | 180 |
Shares Outstanding (Diluted) | 382 | 373 | 311 | 260 | 194 | 180 |
Shares Change (YoY) | 16.61% | 20.10% | 19.57% | 33.86% | 7.97% | 166.96% |
EPS (Basic) | -0.90 | -0.90 | -1.10 | -1.30 | -1.00 | -0.60 |
EPS (Diluted) | -0.90 | -0.90 | -1.10 | -1.30 | -1.00 | -0.60 |
Free Cash Flow | -266.4 | -268.5 | -227.9 | -278.4 | -173.5 | -130.3 |
Free Cash Flow Per Share | -0.70 | -0.72 | -0.73 | -1.07 | -0.89 | -0.72 |
Gross Margin | 14.10% | 19.87% | 74.84% | 80.90% | 72.12% | 79.32% |
Operating Margin | -583.52% | -544.71% | -714.53% | -563.89% | -876.55% | -276.70% |
Profit Margin | -403.33% | -547.60% | -743.82% | -567.53% | -857.52% | -273.56% |
FCF Margin | -422.19% | -430.29% | -494.36% | -483.33% | -767.70% | -341.10% |
EBITDA | -368.2 | -339.9 | -329.4 | -324.8 | -198.1 | -105.7 |
EBIT | -368.2 | -339.9 | -329.4 | -324.8 | -198.1 | -105.7 |
EBIT Margin | -583.52% | -544.71% | -714.53% | -563.89% | -876.55% | -276.70% |
Effective Tax Rate | 0.11% | 0.12% | 0.09% | 0.03% | 0.00% | 0.00% |